This is a routine PDMR sale with no material impact. Monitor for any cluster of insider selling by multiple executives, which would be a more meaningful signal. The sale is not indicative of operational issues at GSK.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 24 $51.78entry
- T+1 · 3mo ago +0.56%α +0.24% · $52.07
- T+5 · 3mo ago −2.95%α −3.42% · $50.25
- T+20 · 8w ago −2.05%α −3.35% · $50.72
- T+59 · todayOpen
- T+60 · in 9h Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK's US President, Maya Martinez-Davis, sold a total of 44,397 American Depositary Shares (ADS) over two days (Aug 20-21, 2026) at approximately $52.14 per share, for total proceeds of about $2.3 million. This is a routine insider sale by a senior executive and does not signal any change in company fundamentals or strategy.
Key Facts
- Maya Martinez-Davis, President US of GSK, sold 3,916 ADS on Aug 20, 2026 at $52.14.
- Maya Martinez-Davis sold 40,481 ADS on Aug 21, 2026 at a weighted average price of $52.1437.
- Total ADS sold: 44,397, total proceeds approximately $2.3 million.
- The sales were executed on the New York Stock Exchange and reported via Form 6-K on Aug 24, 2026.
Financial Impact
Total insider sale proceeds of approximately $2.3 million, representing a de minimis fraction of GSK's $106.1B market cap.
Risk Factors
- Insider selling by a senior US executive could be misinterpreted by the market as a lack of confidence, though the amount is trivial relative to market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007810 |
| Document: 0001654954-26-007810-index-headers.html | 0001654954-26-007810 |
| Document: 0001654954-26-007810-index.html | 0001654954-26-007810 |
| Document: 0001654954-26-007810.txt | 0001654954-26-007810 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers